Savillex, LLC has completed its acquisition of Entegris, Inc.’s Life Sciences Fluid Management business, adding a portfolio focused on bioprocessing and pharmaceutical manufacturing. Savillex is headquartered in Eden Prairie, Minn., and Entegris in Billerica, Mass. The companies did not disclose the transaction terms.
The acquired business brings together high-purity fluid-handling products with Savillex’s existing life sciences offerings. Its portfolio includes bioprocessing and pharmaceutical manufacturing solutions, notably Aramus and PE bags, single-use assemblies, and components used in discovery, clinical and commercial manufacturing. Savillex said the addition broadens its range of high-performance single-use solutions.
Portfolio and customer offer
According to Savillex, customers can expect an expanded set of single-use solutions, more technical expertise and added capabilities spanning early-stage research through commercial manufacturing. The company said combining the two businesses’ complementary strengths should help customers manage increasingly complex bioprocessing workflows and deliver greater value.
The acquisition also brings the Life Sciences Fluid Management team and its high-purity fluid-management technologies into Savillex. The company framed the deal as a way to support critical applications across the drug-development continuum, from discovery work to commercial production.
Executive comments
Eric Giesing, chief executive officer of Savillex, said the Life Sciences Fluid Management business has established a strong reputation in high-purity single-use bioprocessing, and he described the Aramus product line as a natural fit alongside Savillex’s Containment and Bioprocessing offerings. He said the transaction expands the company’s portfolio and should allow it to offer a broader range of solutions to biopharmaceutical and pharmaceutical customers. Giesing also said Savillex is pleased to welcome the team and will continue investing in technologies intended to help customers accelerate development and production of critical therapies.
Chris Bedi, general manager of Fluid Management at Savillex, said the acquisition creates an opportunity to bring a wider portfolio of high-value fluid-management solutions to pharmaceutical and biopharmaceutical customers worldwide. He said the Fluid Management portfolio complements Savillex’s existing capabilities and that the combined organization will continue providing innovative solutions while expanding support for partners throughout drug development. Bedi added that the company is eager to help customers bring new medicines to patients.
Savillex said the acquisition advances its strategy of providing industry-leading solutions for the life sciences market. The company said it remains committed to investment in innovation, quality and customer partnerships as it expands its portfolio for biopharmaceutical and pharmaceutical manufacturers. EC M&A served as financial adviser to Savillex, and Sidley Austin LLP served as legal counsel.